

# MARKET REPORT



HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase strand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Human Immunodeficiency Virus (Hiv) Attacks The Body's Immune System, Making The Host System Susceptible To Infection, And Thus Leading To Complete Damage. The Virus Attacks The Cd4 Cells, Which Help The Immune System Defend Infections. The Major Route Of Transmission Of Hiv Infection Is Through Unprotected Sex, Use Of Contaminated Needle, Breast Milk Of The Hiv Infected Mother, And Infected Blood.

The Global Hiv Drugs Market Was Valued At \$20,448 Million In 2015, And Is Estimated To Reach \$26,458 Million By 2022, Growing At A Cagr Of 3.7% During The Forecast Period From 2016 To 2022. The Major Factors That Boost The Growth Of The Market Include Increase In Prevalence Of Hiv Globally And Rise In Treatment & Diagnosis Rate. Moreover, Growth In Awareness About The Treatment Options & Care With The Various Initiatives And Education Campaigns Introduced By Government Agencies Across The Globe Plays An Important Role In The Growth Of Hiv Drugs Market. However, Stringent Government Regulations For The Approval And Commercialization Of Hiv Drugs Is Expected To Restrain The Growth Of The Hiv Drugs Market.

The Report Segments The Market Based On Medication Class And Geography. On The Basis Of Medication Class, The Market Is Divided Into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Protease Inhibitors (Pis), Fusion Inhibitors (Fi), Entry Inhibitors, Hiv Integrase Stand Transfer Inhibitors. Based On Geography, The Market Is Analyzed Across North America, Europe, Asia-Pacific, And Lamea. The North American Region Accounted For Around Half Of The Share In The Overall Hiv Drug Market In 2015, And Is Expected To Maintain This Lead Throughout The Forecast Period. The Growth In The Hiv Drug Market In The Region Is Attributed To Well-Established Healthcare System, Higher Diagnosis & Treatment Rate In The Region, And Development And Increase In The Adoption Of Advanced Treatment Options From The Hiv Infected Population.

Key Benefits for Stakeholders

The Study Provides An In-Depth Analysis Of The Hiv Drugs Market, With Current Trends And Future Estimations To Elucidate The Imminent Investment Pockets.

It Presents A Quantitative Analysis From 2014 To 2022 To Enable The Stakeholders To Capitalize On Prevailing Market Opportunities.

Extensive Analysis Of The Hiv Drug Market, By Medication Class, Assists In The Effective Treatment Of Hiv/Aids.

Key Players Are Profiled And Their Strategies Are Analyzed Thoroughly, Which Predicts The Competitive Outlook Of The Market.

HIV Drug Market Key Segments

By Medication Class

Multi-Class Combination Drugs

Atriplan

Complera

Prezcobix/Prezista

Stribild

Triumeq

Nucleoside Reverse Transcriptase Inhibitors (Nrtis)

Combivir

Emtriva

Epivir

Epzicom

Trizivir

Truvad

Viread

Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)

Edurant

Intelenc

Rescriptor

Sustiva

Viramune (Immediate Release)

Protease Inhibitors (Pis)

Aptivus

Crixivan

Kaletra

Lexiva

Norvir

Reyataz

Viracept

Fusion Inhibitors (Fi)

Fuzeon

Entry Inhibitors

Selzentry

Hiv Integrase Stand Transfer Inhibitors

Isentress

Tivicay

By Geography

North America

Europe

Asia-Pacific

Lamea

List Of Key Players Profiled in the Report

Boehringer Ingelheim International GmbH

Merck & Co.

Bristol-Myers Squibb

Gilead Sciences Inc.

Viiv Healthcare

Johnson & Johnson

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Abbvie

Cipla Limited

List Of Other Players in the Value Chain

(These Players Are Not Profiled In The Report. The Same Will Be Included On Request)

Daiichi Sankyo

Emcure

Hetero Drugs

Mylan

Astrazeneca

## Additional Details

**Publisher :** Allied Market Research

**Reference :** LI 171867

**Number of Pages :** 163

**Report Format :** PDF

**Publisher Information :**



**Allied Market Research**  
Diligent Intelligence - Improved Growth

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase strand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 23-02-2017]

## • CHAPTER 1 INTRODUCTION

### 1.1. REPORT DESCRIPTION

### 1.2. KEY BENEFITS

### 1.3. KEY MARKET SEGMENTS

### 1.4. RESEARCH METHODOLOGY

#### 1.4.1. Secondary research

#### 1.4.2. Primary research

#### 1.4.3. Analyst tools and models

## CHAPTER 2 EXECUTIVE SUMMARY

### 2.1. CXO PERSPECTIVE

## CHAPTER 3 MARKET OVERVIEW

### 3.1. MARKET DEFINITION AND SCOPE

### 3.2. KEY FINDINGS

#### 3.2.1. Top investment pockets

#### 3.2.2. Top winning strategies

### 3.3. MARKET SHARE ANALYSIS

### 3.4. PRODUCT PIPELINE ANALYSIS

### 3.5. MARKET DYNAMICS

## CHAPTER 4 HIV DRUGS MARKET, BY MEDICATION CLASS

### 4.1. OVERVIEW

### 4.2. MULTI-CLASS COMBINATION DRUGS

#### 4.2.1. Key market trends

#### 4.2.2. Key growth factors and opportunities

#### 4.2.3. Market size and forecast

#### 4.2.4. Atripla: market size and forecast

#### 4.2.5. Complera: market size and forecast

#### 4.2.6. Prezista: market size and forecast

#### 4.2.7. Stribild: market size and forecast



4.2.8. Triumeq: market size and forecast

#### 4.3. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)

4.3.1. Key market trends

4.3.2. Key growth factors and opportunities

4.3.3. Market size and forecast

4.3.4. Combivir: market size and forecast

4.3.5. Emtriva: market size and forecast

4.3.6. Epivir: market size and forecast

4.3.7. Epzicom: market size and forecast

4.3.8. Trizivir: market size and forecast

4.3.9. Truvada: market size and forecast

4.3.10. Viread: market size and forecast

#### 4.4. NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)

4.4.1. Key market trends

4.4.2. Key growth factors and opportunities

4.4.3. Market size and forecast

4.4.4. Edurant: market size and forecast

4.4.5. Rescriptor: market size and forecast

4.4.6. Sustiva: market size and forecast

4.4.7. Viramune: market size and forecast

#### 4.5. PROTEASE INHIBITORS (PIS)

4.5.1. Key market trends

4.5.2. Key growth factors and opportunities

4.5.3. Market size and forecast

4.5.4. Aptivus: market size and forecast

4.5.5. Crixivan: market size and forecast

4.5.6. Kaletra: market size and forecast

4.5.7. Lexiva: market size and forecast

4.5.8. Norvir: market size and forecast

4.5.9. Reyataz: market size and forecast

4.5.10. Viracept: market size and forecast

#### 4.6. FUSION INHIBITORS

4.6.1. Key market trends

4.6.2. Key growth factors and opportunities

4.6.3. Market size and forecast

4.6.4. Fuzeon: market size and forecast

#### 4.7. ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST

4.7.1. Key market trends

4.7.2. Key growth factors and opportunities

4.7.3. Market size and forecast

4.7.4. Selzentry: market size and forecast

#### 4.8. HIV INTEGRASE STRAND TRANSFER INHIBITORS

4.8.1. Key market trends

4.8.2. Key growth factors and opportunities

- 4.8.3. Market size and forecast
- 4.8.4. Isentress: market size and forecast
- 4.8.5. Tivicay: market size and forecast

## CHAPTER 5 HIV DRUGS MARKET, BY GEOGRAPHY

### 5.1. OVERVIEW

- 5.1.1. Market size and forecast

### 5.2. NORTH AMERICA

- 5.2.1. Key market trends
- 5.2.2. Key growth factors and opportunities
- 5.2.3. Market size and forecast

### 5.3. EUROPE

- 5.3.1. Key market trends
- 5.3.2. Key growth factors and opportunities
- 5.3.3. Market size and forecast

### 5.4. ASIA-PACIFIC

- 5.4.1. Key market trends
- 5.4.2. Key growth factors and opportunities
- 5.4.3. Market size and forecast

### 5.5. LAMEA

- 5.5.1. Key market trends
- 5.5.2. Key growth factors and opportunities
- 5.5.3. Market size and forecast

## CHAPTER 6 COMPANY PROFILES

### 6.1. BOEHRINGER INGELHEIM INTERNATIONAL GMBH

- 6.1.1. Overview
- 6.1.2. Operating business segments
- 6.1.3. Business performance
- 6.1.4. Key strategic moves & developments

### 6.2. MERCK & CO., INC.

- 6.2.1. Overview
- 6.2.2. Operating business segments
- 6.2.3. Business performance
- 6.2.4. Key strategic moves & developments

### 6.3. BRISTOL-MYERS SQUIBB

- 6.3.1. Overview
- 6.3.2. Operating business segments
- 6.3.3. Business performance
- 6.3.4. Key strategic moves & developments

## 6.4. GILEAD SCIENCES, INC.

- 6.4.1. Overview
- 6.4.2. Operating business segments
- 6.4.3. Business performance
- 6.4.4. Key strategic moves & developments

## 6.5. VIIV HEALTHCARE

- 6.5.1. Overview
- 6.5.2. Operating business segments
- 6.5.3. Business performance
- 6.5.4. Key strategic moves & developments

## 6.6. JOHNSON & JOHNSON

- 6.6.1. Overview
- 6.6.2. Operating business segments
- 6.6.3. Business performance
- 6.6.4. Key Strategic Moves & Developments

## 6.7. F. HOFFMANN-LA ROCHE LTD

- 6.7.1. Overview
- 6.7.2. Operating business segments
- 6.7.3. Business performance
- 6.7.4. Key Strategic Moves & Developments

## 6.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.

- 6.8.1. Overview
- 6.8.2. Operating business segments
- 6.8.3. Business performance
- 6.8.4. Key Strategic Moves & Developments

## 6.9. ABBVIE

- 6.9.1. Overview
- 6.9.2. Operating business segments
- 6.9.3. Business performance
- 6.9.4. Key strategic moves & developments

## 6.10. CIPLA

- 6.10.1. Overview
- 6.10.2. Operating business segments
- 6.10.3. Business performance
- 6.10.4. Key Strategic Moves & Developments

## LIST OF OTHER PLAYERS IN THE VALUE CHAIN

(These players are not profiled in the report. The same will be included on request)



Emcure

Hetero Drugs

Mylan

AstraZeneca

## LIST OF TABLES

TABLE 1. HIV PRODUCT PIPELINE: ANTIVIRALS

TABLE 2. HIV PRODUCT PIPELINE: CELL THERAPY/GENE THERAPY

TABLE 3. HIV PRODUCT PIPELINE: IMMUNOMODULATORS

TABLE 4. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 (\$MILLION)

TABLE 5. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 6. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY BRAND, 2014-2022 (\$MILLION)

TABLE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 (\$MILLION)

TABLE 9. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 10. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY BRAND TYPE, 2014-2022 (\$MILLION)

TABLE 11. GLOBAL PROTEASE INHIBITORS (PI) MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 12. GLOBAL PROTEASE INHIBITORS (PI) MARKET, BY BRAND TYPE, 2014-2022 (\$MILLION)

TABLE 13. GLOBAL FUSION INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 14. GLOBAL ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 15. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 16. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 (\$MILLION)

TABLE 17. GLOBAL HIV DRUGS MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)

TABLE 18. NORTH AMERICA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 (\$MILLION)

TABLE 19. EUROPE: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 (\$MILLION)

TABLE 20. AISA-PACIFIC: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 (\$MILLION)

TABLE 21. LAMEA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 (\$MILLION)

TABLE 22. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT

TABLE 23. BOEHRINGER INGELHEIM: OPERATING SEGMENTS

TABLE 24. MERCK: COMPANY SNAPSHOT

TABLE 25. MERCK: OPERATING SEGMENTS

TABLE 26. BMS: COMPANY SNAPSHOT

TABLE 27. GILEAD: COMPANY SNAPSHOT

TABLE 28. VIIV HEALTHCARE: COMPANY SNAPSHOT

TABLE 29. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 30. JOHNSON & JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 31. ROCHE: COMPANY SNAPSHOT

TABLE 32. ROCHE: OPERATING SEGMENTS

TABLE 33. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT

TABLE 34. TEVA: OPERATING SEGMENTS

TABLE 35. ABBVIE: COMPANY SNAPSHOT

TABLE 36. CIPLA LIMITED: COMPANY SNAPSHOT

## LIST OF FIGURES

FIGURE 1. HIV DRUGS: MARKET SEGMENTATION  
FIGURE 2. TOP INVESTMENT POCKETS  
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016  
FIGURE 4. HIV DRUGS MARKET SHARE ANALYSIS, 2015  
FIGURE 5. PRODUCT PIPELINE ANALYSIS  
FIGURE 6. GLOBAL ATRIPLA MARKET, 2014-2022 (\$MILLION)  
FIGURE 7. GLOBAL COMPLERA MARKET, 2014-2022 (\$MILLION)  
FIGURE 8. GLOBAL PREZISTA MARKET, 2014-2022 (\$MILLION)  
FIGURE 9. GLOBAL STRIBILD MARKET, 2014-2022 (\$MILLION)  
FIGURE 10. GLOBAL TRIUMEQ MARKET, 2014-2022 (\$MILLION)  
FIGURE 11. GLOBAL COMBIVIR MARKET, 2014-2022 (\$MILLION)  
FIGURE 12. GLOBAL EMTRIVA MARKET, 2014-2022 (\$MILLION)  
FIGURE 13. GLOBAL EPIVIR MARKET, 2014-2022 (\$MILLION)  
FIGURE 14. GLOBAL EPZICOM MARKET, 2014-2022 (\$MILLION)  
FIGURE 15. GLOBAL TRIZIVIR MARKET, 2014-2022 (\$MILLION)  
FIGURE 16. GLOBAL TRUVADA MARKET, 2014-2022 (\$MILLION)  
FIGURE 17. GLOBAL VIREAD MARKET, 2014-2022 (\$MILLION)  
FIGURE 18. GLOBAL EDURANT MARKET, 2014-2022 (\$MILLION)  
FIGURE 19. GLOBAL INTELENCE MARKET, 2014-2022 (\$MILLION)  
FIGURE 20. GLOBAL RESCRIPTOR MARKET, 2014-2022 (\$MILLION)  
FIGURE 21. GLOBAL SUSTIVA MARKET, 2014-2022 (\$MILLION)  
FIGURE 22. GLOBAL VIRAMUNE MARKET, 2014-2022 (\$MILLION)  
FIGURE 23. GLOBAL APTIVUS MARKET, 2014-2022 (\$MILLION)  
FIGURE 24. GLOBAL CRIVIVAN MARKET, 2014-2022 (\$MILLION)  
FIGURE 25. GLOBAL KALETRA MARKET, 2014-2022 (\$MILLION)  
FIGURE 26. GLOBAL LEXIVA MARKET, 2014-2022 (\$MILLION)  
FIGURE 27. GLOBAL NORVIR MARKET, 2014-2022 (\$MILLION)  
FIGURE 28. GLOBAL REYATAZ MARKET, 2014-2022 (\$MILLION)  
FIGURE 29. GLOBAL VIRACEPT MARKET, 2014-2022 (\$MILLION)  
FIGURE 30. GLOBAL FUZEON MARKET, 2014-2022 (\$MILLION)  
FIGURE 31. GLOBAL SELZENTRY MARKET, 2014-2022 (\$MILLION)  
FIGURE 32. GLOBAL ISENTRESS MARKET, 2014-2022 (\$MILLION)  
FIGURE 33. GLOBAL TIVICAY MARKET, 2014-2022 (\$MILLION)  
FIGURE 34. BOEHRINGER INGELHEIM: REVENUE, 2013-2015 (\$MILLION)  
FIGURE 35. MERCK: REVENUE, 2013-2015 (\$MILLION)  
FIGURE 36. BMS: REVENUE, 2013-2015 (\$MILLION)  
FIGURE 37. GILEAD: REVENUE, 2013-2015 (\$MILLION)  
FIGURE 38. JOHNSON & JOHNSON: REVENUE, 2013-2015, (\$MILLION)  
FIGURE 39. ROCHE: REVENUE, 2013-2015, (\$MILLION)  
FIGURE 40. TEVA: REVENUE, 2013-2015, (\$MILLION)  
FIGURE 41. ABBVIE: REVENUE, 2013-2015 (\$MILLION)  
FIGURE 42. CIPLA: REVENUE, 2013-2015 (\$MILLION)

# How to Buy...

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 23-02-2017]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/103456>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$5370** | Single User Price
- \$5910** | Five User License Price
- \$7800** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.